<DOC>
	<DOCNO>NCT02716415</DOCNO>
	<brief_summary>The purpose study compare efficacy safety Calmoseptine Ointment Desitin Maximum Strength 40 % Zinc Oxide Diaper Rash Paste treatment diaper dermatitis among Neonates Infants .</brief_summary>
	<brief_title>Trial Comparing Calmoseptine Ointment Desitin Diaper Rash Paste Diaper Dermatitis Neonates Infants</brief_title>
	<detailed_description>This single-center , randomize , control , assessor-blinded clinical trial . Neonates born UP-PGH infant ( &lt; 1 year age ) general pediatric ward condition diaper dermatitis recruit randomized treatment either Calmoseptine Ointment Desitin Maximum Strength 40 % Zinc Oxide Diaper Rash Paste part structure skin care regimen . Each participant one week total participation , unless withdrawn . Baseline data collect study treatment initiate study entry day . Treatment continue follow data collect six subsequent follow day . Primary outcome : healing Diaper Dermatitis six day treatment , define Diaper Dermatitis Severity Score zero attribute blinded assessment . Secondary outcome : Diaper Dermatitis Severity Score day treatment ; size affect area ; incidence Candida infection ; adverse event . Zinc Oxide Ointment preparation include Calmoseptine Ointment Desitin Maximum Strength 40 % Diaper Rash Paste use treat diaper dermatitis many year around world . There know report hypersensitivity either product report serious adverse event . As propose study neonates infant , precaution evidence relate safety toxicity individual ingredient review trial protocol prior commencement .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Diaper Rash</mesh_term>
	<mesh_term>Zinc</mesh_term>
	<mesh_term>Menthol</mesh_term>
	<mesh_term>Zinc Oxide</mesh_term>
	<criteria>1 . The child participant must &lt; 1 year age . 2 . The participant must , upon clinical inspection investigator , assess diaper dermatitis â‰¥ Grade 2 accord study 's diaper dermatitis severity scale ( see `` Primary Outcome '' ) . 3 . The participant 's parent , next kin legally acceptable representative agree child 's inclusion sign inform consent . 4 . The participant 's primary physician agree inclusion . 5 . There reasonable expectation participant hospitalize least 7 day able complete study . ( NB Study Participant Withdrawal Criteria b Any participant discharge hospital attend physician completion study participation automatically withdraw study . Study participation circumstance lead delay participant 's discharge hospital . ) 6 . Participant know allergy history adverse reaction ingredient either product topical preparation skin care product 1 . Participants preexist full thickness wound within study area . 2 . Participants preexist active dermatological condition ( ) , DD , may affect heal interpretation trial result . Where uncertainty exist , Investigators arrange consultation Consultant Dermatologist . 3 . Participant history recurrent dermatological condition , DD , may imply difficult heal affect interpretation trial result . 4 . Participant severe acute chronic medical condition trial participation may constitute risk , may interfere medical care , affect interpretation result , attend physician advises participation . 5 . Participant systemic antifungal treatment ( eg . Amphotericin B Fluconazole ) , topical antifungal treatment / systemic topical corticosteroid . 6 . Participant precede week treat topical agent may affect healing ( e.g . dimethicone base ointment , zinc oxide powder , petroleum jelly )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Months</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>neonate</keyword>
	<keyword>infant</keyword>
</DOC>